Alector, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology treatments, with no approved products and no product-sales revenue. Its principal clinical programs are latozinemab, AL101 and AL002.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Collaboration revenue | $133.6 million | $207.1 million |
| Research and development expense | $210.4 million | $189.4 million |
| General and administrative expense | $61.0 million | $55.0 million |
| Operating loss | $137.8 million | $37.4 million |
| Net loss | $133.3 million | $36.3 million |
| Operating cash flow | $(20.3) million | $298.6 million |
- FY 2022 operating margin was approximately -103% and net margin approximately -100%, calculated from reported revenue and losses. These margins reflect collaboration revenue, not product sales.
- At year-end, cash and cash equivalents were $154.3 million and marketable securities were $558.5 million, totaling $712.9 million. Management expects these resources to fund operations through 2025, based on its current operating plan and assumptions.
- Current assets were $726.4 million versus current liabilities of $93.8 million. Total liabilities were $573.2 million, including $491.6 million of deferred collaboration revenue and $43.3 million of operating lease liabilities. The filing reports no conventional borrowings.
- Accumulated deficit was $579.7 million. The company reported $46.1 million of stock-based compensation in 2022.
Material changes and notable items
- Revenue fell $73.5 million year over year, principally because $173.4 million of revenue from the GSK latozinemab FTD-GRN license was recognized in 2021. The decline was partly offset by increased revenue recognized over time for GSK and AbbVie programs.
- Operating expenses increased $27.0 million. R&D rose $21.0 million, including higher personnel costs and AL002 development spending; lower latozinemab expense partly offset the increase. G&A rose $6.0 million.
- Net loss widened to $133.3 million from $36.3 million. 2021 operating cash inflow was substantially affected by GSK’s $500 million upfront payment; 2022 included the remaining $200 million payment, received in January 2022. Operating cash flow is therefore affected by collaboration-payment timing and deferred-revenue accounting.
- Investment activity used $159.0 million of cash, primarily reflecting purchases of marketable securities net of maturities. Financing provided $4.5 million, largely from option exercises.
- Marketable securities included $133.2 million of U.S. Treasury securities in an unrealized-loss position for over 12 months; the company said it did not intend to sell them and was unlikely to need to sell before recovery or maturity.
Outlook, programs and risks
- Latozinemab: INFRONT-3, a pivotal Phase 3 FTD-GRN trial, was ongoing. Alector targeted a readout in early 2025, subject to regulatory feedback, and planned mid-2023 discussions with regulators on trial analyses that might permit fewer participants or a shorter treatment period. Earlier open-label Phase 2 results included an estimated 48% slowing of clinical progression versus matched historical controls; these results are not confirmatory pivotal-trial evidence.
- AL002: INVOKE-2 Phase 2 enrollment was expected to finish in Q3 2023, with topline data expected in Q4 2024. ARIA, including a small number of serious events, prompted discontinuation of dosing and enrollment for APOE e4/e4 participants and earlier MRI monitoring. Serious events were also observed in a small number of non-homozygous participants.
- AL101: Following Phase 1 results showing dose-dependent increases in PGRN and general tolerability in healthy volunteers, Alector and GSK planned an Asian PK-bridging study followed by a global Phase 2 study in early Alzheimer’s disease.
- Portfolio changes: Alector said it had prioritized PGRN and TREM2 programs to extend cash runway through 2025. AL044 Phase 1 was closed based on initial PK and tolerability data; the company was pursuing a backup MS4A candidate. AbbVie discontinued the AL003/CD33 program, and Innovent would not continue AL008 development; Alector intended to reacquire AL008 rights and evaluate available data.
- Alector and GSK may receive up to $1.5 billion in additional development, regulatory and commercial milestones under their collaboration. In February 2023, Alector and AbbVie amended their agreement, providing for a $17.8 million milestone payment after the first patient was dosed in an AL002 long-term extension study. AbbVie also has a $250 million option for the TREM2 program, plus up to $225 million in regulatory milestones.
- Key risks include clinical-trial failure or delay, patient enrollment and safety, evolving regulatory standards for neurodegenerative diseases, reliance on collaborators and third-party manufacturers, competition, and potential need for additional capital. Management’s runway estimate depends on assumptions and could prove inaccurate. Inflation and supply-chain disruption may also increase costs.
Most important facts for investors to verify
- Cash, marketable securities, spending trends and the assumptions supporting management’s runway-through-2025 estimate.
- INFRONT-3 regulatory feedback, trial design and enrollment progress, and the timing and evidentiary strength of its pivotal results.
- INVOKE-2 ARIA incidence and severity, monitoring measures, enrollment status and topline-data timing.
- Whether planned AL101 studies proceed, and the status and economics of the GSK and AbbVie collaborations, including milestone conditions and cost-sharing obligations.
- The practical effect of program prioritization and discontinued programs on future R&D spending, collaboration revenue and portfolio prospects.
The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting as of December 31, 2022.